Farmington Hills, MI (April 25, 2007)--- A Botsford Hospital physician led a study that improves patient function and quality of life for patients struggling with pulmonary disease.
As one of the lead researchers on an international study, Gary T. Ferguson, M.D., Medical Director of Botsford Hospital’s Respiratory Department, and his colleagues looked at 6,000 patients with chronic obstructive pulmonary disease (COPD) and the affect of the medication Advair on mortality. Dr. Ferguson says, “The medication was shown to improve mortality, reduce hospitalization and increase quality of life. This is a revolutionary study because it is the first time a medication has been shown to impact mortality in COPD.”
This project, called the TORCH study, was published in The New England Journal of Medicine (NEJM) on February 22, 2007. Dr. Ferguson says, “The importance of this research is highlighted by its publication in the NEJM. For many years, we have had little to offer our COPD patients. With studies such as this, we are now starting to identify therapies that may truly impact our patient lives.”
Botsford Hospital, an independent, acute care, 330-bed community hospital in Farmington Hills, Mich., was founded in 1965. Nationally recognized for quality, safety and medical education programs, Botsford has received the 2005 Solucient 100 Top Hospitals: Performance Improvement Leaders award and the 2005 Governor’s Award of Excellence for Improving Care in the Hospital and Emergency Department Settings. Botsford’s Web address is www.botsford.org.
MEDIA CONTACT: Nancy Dumas, Beth Montalvo or Stacy Brand
PHONE: (248) 442-7986